Nesrine Chraiet
Tunis El Manar University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Nesrine Chraiet.
Oral Oncology | 2012
Aymen Lagha; Nesrine Chraiet; Mouna Ayadi; Sarra Krimi; Bassem Allani; Hela Rifi; Henda Raies; Amel Mezlini
Salivary gland cancers are very rare tumors. They are characterized by a histologic heterogeneity and a poor outcome. According to this rarity, few prospective data are available to date. No standard recommendations could be held for the use of systemic therapy in these tumors. Several case reports and small studies have investigated the contribution of different agents of chemotherapy. With the extension of molecular biology approach in oncology several signaling pathways have been discovered in different cancers including salivary gland cancers; thus a number of targeted therapies have been investigated. This paper reviewed exhaustively the studies investigating the role of systemic therapies (chemotherapy, targeted therapy, hormone therapy) in salivary gland cancers.
Critical Reviews in Oncology Hematology | 2013
Aymen Lagha; Nesrine Chraiet; Soumaya Labidi; Hela Rifi; Mouna Ayadi; Sarra Krimi; Bassem Allani; Henda Raies; S. Touati; Hamouda Boussen; Lotfi Kochbati; Amel Mezlini
The concept of larynx preservation in locally advanced laryngeal or hypopharyngeal squamous cell carcinoma has evolved during the last three decades, especially with the advancement of nonsurgical strategies. These nonsurgical strategies include: (1) radiotherapy alone; (2) concomitant chemoradiotherapy (CCRT); and (3) induction chemotherapy followed by radiotherapy or CCRT and concurrent anti-epidermal growth factor receptor (EGFR). To date, the best approach for larynx preservation has yet to be defined. In this article, we review and discuss important recent randomized phase II/III trials investigating larynx preservation in order to facilitate the selection of an appropriate strategy in the clinical setting. However, the decision of larynx preservation should always be a multidisciplinary approach.
American Journal of Case Reports | 2012
Aymen Lagha; Mouna Ayadi; Sarra Krimi; Nesrine Chraiet; Bassem Allani; Hela Rifi; Henda Raies; Amel Mezlini
Summary Background: Anorectal melanoma is a rare and aggressive disease. The mainstay of treatment is usually surgical with curative or palliative intent, since radio- and chemotherapy do not really improve the outcome. The poor prognosis is attributable to delay in diagnosis and its inherent biologic aggressiveness. Case Report: We present a case of anorectal melanoma in a 68-year-old man who underwent solely abdominoperineal amputation and was doing well 30 months after surgery, without any evidence of recurrent disease. Conclusions: Treatment of anorectal melanoma should be by the least morbid means possible. Surgical procedure that can achieve a complete local excision and respect the functional aspects and quality of life of the patient remains the best therapeutic approach. No systemic regimen for metastatic anorectal melanoma is considered standard of care.
Urology case reports | 2018
Amina Mokrani; Fatma Guermazi; Khedija Meddeb; Linda Bel Hadj Kacem; Marouene Chakroun; Yosra Yahyaoui; Feriel Letaief; Azza Gabsi; A. Bouzouita; Mouna Ayadi; Nesrine Chraiet; Henda Raies; Soumaya Rammeh; Mohamed Chebil; Amel Mezlini
a Department of Oncology, Salah Azaiez Institute, Faculty of Medicine of Tunis, Boulevard 9 Avril, Tunis El Manar University, Tunis, France Department of Pathology, Charles Nicolle Hospital, Faculty of Medicine of Tunis, Boulevard 9 Avril, Tunis El Manar University, Tunis, France c Department of Urology, Charles Nicolle Hospital, Faculty of Medicine of Tunis, Boulevard 9 Avril, Tunis El Manar University, Tunis, France
Urology case reports | 2018
Amina Mokrani; Fatma Guermazi; Khedija Meddeb; Yosra Yahyaoui; Feriel Letaief; Azza Gabsi; Mouna Ayadi; Nesrine Chraiet; Henda Raies; Amel Mezlini
Paratesticular adult rhabdomyosarcoma (RMS) is a rare pathology that has the specificity of being more aggressive than that of the child. It has high malignant potential, quick spread and requires prompt and adequate care. In this context we report the case of an adult paratesticular RMS. We aimed to describe its clinical features and natural history.
Urology case reports | 2018
Azza Gabsi; Yosra Yahiaoui; Alia Zenhani; Kaouther Herbegue; Khedija Meddeb; Amina Mokrani; Feryel Letaief; Mouna Ayadi; Henda Rais; Nesrine Chraiet; Slim Haouet; Amel Mezlini
Breast cancer is now the most frequently diagnosed cancer and first cause of cancer death in women worldwide with the highest mortality rate due to its metastasis. The most commun sites of metastasis are bone, lungs, liver, and pleura.1 Metastasis to the ureter is rare. Neoplasms of the stomach, breast, urinary bladder and prostate are the primary tumors that most frequently metastasize to the ureter and about 7.8% are metastases from carcinoma of the breast.1
The Pan African medical journal | 2018
Rim Batti; Feryel Letaief; Haifa Rachdi; Asma Zidi; Sonia Sghaier; Mouna Ayadi; Khadija Meddeb; Amina Mokrani; Yosra Yahyaoui; Henda Raies; Nesrine Chraiet; Amel Mezlini
Primary lung lymphomas are rare tumors representing less than 1% of malignant tumors of the lung. The most frequent form is the mucosa-associated lymphoid tissue (MALT). Ocular involvement is also rare and it is mostly located in the lachrymal glands. We report the case of a patient with pulmonary MALT lymphoma associated with synchronous involvement of the lachrymal glands. This study illustrates the nonspecific clinical, radiological and evolutionary features of this disease.
International Journal of Surgical Oncology | 2018
Manel Dridi; Nesrine Chraiet; Rim Batti; Mouna Ayadi; Amina Mokrani; Khedija Meddeb; Yosra Yahiaoui; Henda Raies; Amel Mezlini
Background Adult granulosa cell tumors (AGCTs) are the most common sex cord-stromal tumors. Unlike epithelial ovarian tumors, they occur in young women and are usually detected at an early stage. The aim of this study was to report the clinical and pathological characteristics of AGCT patients and to identify the prognostic factors. Methods All cases of AGCTs, treated at Salah Azaïz Institute between 1995 and 2010, were retrospectively included. Kaplan-Meiers statistical method was used to assess the relapse-free survival and the overall survival. Results The final cohort included 31 patients with AGCT. The mean age was 53 years (35–73 years). Patients mainly presented with abdominal mass and/or pain (61%, n = 19). Mean tumor size was 20 cm. The majority of patients had a stage I disease (61%, n = 19). Two among 3 patients with stage IV disease had liver metastasis. Mitotic index was low in 45% of cases (n = 14). Surgical treatment was optimal in almost all cases (90%, n = 28). The median follow-up time was 14 years (1–184 months). Ten patients relapsed (32%) with a median RFS of 8.4 years (6.8–9.9 years). Mean overall survival was 13 years (11–15 years). Stage I disease and low-to-intermediate mitotic index were associated with a better prognosis in univariate analysis (resp., p = 0.05 and p = 0.02) but were not independent prognostic factors. Conclusion GCTs have a long natural history with common late relapses. Hence, long active follow-up is recommended. In Tunisian patients, hepatic metastases were more frequent than occidental series. The prognosis remains good and initial staging at diagnosis is an important prognostic factor.
Journal of Cancer Science & Therapy | 2017
Amina Mokrani; Fatma Guermazi; Yosra Yahyaoui; Lina Hmida; Raoudha Doghri; Mouna Ayadi; Meddeb Khedija; Feriel Letaief; Nesrine Chraiet; Henda Raies; Karima Mrad; Amal Mezlini
Background: Primary giant cell tumor (GCT) of soft tissue (GCTST) is an extremely rare slow-growing entity bearing a high similarity to conventional bone TCG (GCTB). The term, malignant tumor of giant cells of soft tissues have been reserved for histologically high-grade lesions. Although the gold standard remains surgical carcinological resection, bisphosphonates are beginning to prove their benefit in the treatment of GCTST. Results and Discussion: A 37-year-old man came to the outpatient department of medical oncology with a painful swelling arising from his right elbow. Magnetic resonance imaging (MRI) of the right elbow was done and revealed a 19 cm × 7 cm, T1 and T2 hypointense lesion with significant postcontrast enhancement of calcified tissue nodules, distance extension report was negative. An echo-guided biopsy of the right elbow was performed. The anatomopathological examination showed a poorly delimited encapsulated tumor proliferation composed of sheets of histiocytic cells admixed with multinucleated giant cells dispersed uniformly among this tumor. Cells were embedded in a richly vascularized tissue. No significant nuclear pleomorphism or mitotic activity was appreciated. There were focal areas of osseous metaplasia. On the basis of these date, the diagnosis of giant cell tumor of low malignant potential was retained. Due to its intra-articular extension, the mass was judged unresecable. The case was discussed in a multidisciplinary consultation meeting indicating medical treatment with zoledronic acid given the unavailability of denosumab. After 8 monthly injections of zoledronic acid, a control imaging of the right elbow and forearm concluded to tumor stability. Conclusion: GCTST is a slow-growing tumor known as soft tissue tumor. Numerous studies show the role of bisphosphonates when complete surgical excision cannot be performed. Further studies are needed to establish a standardized treatment protocol particularly in the context of inoperable large primary GCTST.
Cancer biology and medicine | 2017
Feryel Letaief; Meher Nasri; Mouna Ayadi; Khedija Meddeb; Amina Mokrani; Yosra Yahyaoui; Nesrine Chraiet; Henda Raies; Amel Mezlini
Objective : To assess the response rate of patients with rectal adenocarcinoma to neoadjuvant therapy and to identify the predictors of histological regression after neoadjuvant radiotherapy (RT) or concurrent chemoradiotherapy (CCRT). Methods : This study recruited 64 patients. The patients had resectable cancer of the lower and the middle rectum (T3/T4 and/or N+) without distant metastasis and received neoadjuvant RT or CCRT followed by radical surgery with total mesorectal excision (TME) between January 2006 and December 2011. The patients were classified into non-response (NR), partial response (PR), and pathologic complete response (pCR) based on the Dworak tumor regression grading system. Results : The median age of patients was 57 years (ranging from 22 to 85). A total of 24 patients were treated with neoadjuvant CCRT, whereas 40 patients were treated with RT alone. Abdominoperineal resection (APR) was performed on 29 patients (45%). Anterior resection with TME was performed on 34 patients (53%). One patient had local resection. Histologically, 12 (19%), 24 (73%), and 28 (44%) patients exhibited pCR, PR, and NR, respectively. Univariate analysis revealed that the predictors of tumor regression were as follows: the absence of lymph node involvement from initial imaging (cN0) (P=0.021); normal initial carcinoembryonic antigen (CEA) level (P=0.01); hemoglobin level ≥12 g/dl (P=0.009); CCRT (P=0.021); and tumor downstaging in imaging (P=0.001). Multivariate analysis showed that the main predictors of pCR were CT combined with neoadjuvant RT, cN0 stage, and tumor regression on imaging. Conclusions : Identifying the predictors of pCR following neoadjuvant therapy aids the selection of responsive patients for non-aggressive surgical treatment and possible surveillance.